MET and neoplasm: At the same time, the attractiveness of MET/HGFR and FLT4/VEGFR3 as prognostic biomarkers and targets for anti-metastatic, anti-angiogenic and, since recently, immune therapy for a variety of epithelial malignancies has come from numerous observations that they synergistically contribute to tumor growth (via auto- and paracrine mechanisms), (lymph-)angiogenesis, and tumor cell invasion/migration, and participate in formation of immune tolerance and suppression via immune checkpoint mechanisms [115,116,117].